Antiangiogenic effects of camptothecin analogues 9-amino- 20(S)camptothecin, topotecan, and CPT-11 studied in the mouse cornea model

Clinical Cancer Research

Volumn 5, Issue 1, 1999, Pages 181-187

  O'Leary, James J ^a   Shapiro, Richard L ^a   Ren, Chris J ^a   Chuang, Neal ^a   Cohen, Henry W ^a   Potmesil, Milan ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; BASIC FIBROBLAST GROWTH FACTOR; CAMPTOTHECIN DERIVATIVE; IRINOTECAN; NSC 603071; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DOSE RESPONSE; DRUG EFFECT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SLIT LAMP; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CORNEA; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTOR 2; MICE; MICE, INBRED STRAINS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; TOPOTECAN; VINCRISTINE;

EID: 0032956544     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Potmesil, M. Camptothecins: from bench research to hospital wards. Perspectives in cancer research. Cancer Res., 54: 1431-1439, 1994.
2. Costin, D., and Potmesil, M. DNA topoisomerase II as an intracellular target in cancer chemotherapy by anthracyclines, In: L. F. Liu, (ed.), DNA Topoisomerases: Topoisomerase-targeting Drugs, pp. 51-72. New York: Academic Press, 1994.
3. Potmesil, M., Arbuck, S. G., Takimoto, C. H., Liebes, L., and Hochster, H. 9- Aminocamptothecin and beyond: preclinical and clinical studies. In: P. Pantazis, B. C. Giovanella, and M. L. Rothenberg (eds.), The Camptothecins: From Discovery to the Patient, Vol. 803, 231-247. New York: New York Academy of Sciences, 1996.
4. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Chachoua, A., Raphael, B., Moskovits, T., Taubes, B., Friedberg, A., Buckley, M., Fry, D., Arbuck, S., Blum, R., and Potmesil, M. Phase I and pharmacodynamic study of prolonged infusion 9-aminocamptothecin (9AC) in two formulations. Proc. Am. Assoc. Clin. Oncol., 15: 201a, 1997.
5. Broom, C. Clinical studies of topotecan. In: P. Pantazis, B. C. Giovanella, and M. L. Rothenberg (eds.), The Camptothecins: From Discovery to the Patient, Vol. 803, pp. 264-271. New York: New York Academy of Sciences, 1996.
6. Gordon, A., Bookman, M., Malstrom, H., Bolis, G., Mangioni, C., Hall, J., Carter, J., Hudson, I., and Broom, C. Efficacy of topotecan in advanced ovarian cancer and failure of platinum and paclitaxel: International Topotecan Study Group trial. Proc. Am. Assoc. Clin. Oncol., 14: 282, 1996.
7. Rothenberg, M. The current status of irinotecan (CPT-11) in the United States. In: P. Pantazis, B. C. Giovanella, and M. L. Rothenberg (eds.), The Camptothecins: From Discovery to the Patient, Vol. 803, pp. 272-281. New York: New York Academy of Sciences, 1996.
8. Armand, J. P., Ternet, C., Couteau, C., and Rixe, O. CPT-11: the European experience. In: P. Pantazis, B. C. Giovanella, and M. L. Rothenberg (eds.). The Camptothecins: From Discovery to the Patient, Vol. 803, pp. 282-291. New York: New York Academy of Sciences, 1996.
9. Saito, N. Clinical trials of irinotecan hydrochloride (CPT, campto injection) in Japan. In: P. Pantazis, B. C. Giovanella, and M. L. Rothenberg (eds.), The Camptothecins: From Discovery to the Patient, Vol. 803, pp. 292-305. New York: New York Academy of Sciences, 1996.
10. Von Hoff, D. D., Rothenberg, M. L., Pitot, H. C., Elfring, G. L., Mohrland, J. S., Schaaf, L. J., Neff, L. L., Locker, P. K., Gibson, R. E., and Miller, L. L. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of FDA-reviewed pivotal United States clinical trials. Proc. Am. Assoc. Clin. Oncol., 15: 228a, 1997.
11. Folkman, J. New perspectives in clinical oncology from angiogenesis research. Eur. J. Cancer Res., 32A: 2534-2539, 1996.
12. Holmgren, L., O'Reilly, M. S., and Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1: 149-153, 1995.
13. Mutan, V. R., and Auerbach, R. Angiogenesis in the mouse cornea. Science (Washington DC), 205: 1418-1419, 1979.
14. Kenyon, B. M., Voest, E. E., Chen, C. C., Flynn, E., Folkman, J., and D'Amato, R. J. A model of angiogenesis in the mouse cornea. Invest. Ophthalmol. Visual Sci., 37: 1625-1632, 1996.
15. Klauber, N., Parangi, S., Flynn, E., Hamel, E., and D'Amato, R. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res., 57: 81-86, 1997.
16. Steiner, R. Angiostatic activity of anticancer agents in the chick embryo chorio-allantoic membrane (CHE-CAM) assay. In: R. Steiner, P. B. Weisz, and K. Langer (eds.), Angiogenesis: Key Principles, Science, Technology, Medicine, pp. 449-454. Basel: Birkhauser Verlag, 1992.
17. Dunnett, C. W. A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc., 50: 1096-1121, 1955.
18. Potmesil, M., Giovanella, B. C., Liu, L. F., Wall, M. E., Silber, R., Stehlin, J. S., Hsiang, Y-H., and Wani, M. C. Preclinical studies of DNA topoisomerase I-targeted 9-amino and 10,11-methylenedioxy camptothecins. In: M. Potmesil and K. W. Kohn (eds.), DNA Topoisomerases in Cancer, pp. 299-311. New York: Oxford University Press, 1991.
19. Potmesil, M., and Giovanella, B. C. Preclinical development of 20(S)-camptothecin, 9-aminocamptothecin, and other analogs. In: M. Potmesil and H. Pinedo (eds.), Camptothecins: New Anticancer Agents, pp. 51-57. Boca Raton, FL: CRC Press, 1995.
20. Houghton, P. J., Cheshire, P. J., Myers, L., Steward, C. F., Synold, T. W., and Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
21. Kaneda, N., Nagata, H., Furuta, T., and Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
22. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M. C., Mathieu-Boue, A., and Houghton, J. A. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res., 53: 2823-2829, 1993.
23. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., Vinci, R. Z., and Blum, R. H. Phase-I trial of low dose continuous topotecan infusion in patients with cancer: an active and well tolerated regimen. J. Clin. Oncol., 12: 553-559, 1994.
24. Herbst, R. S., and Teicher, B. A. The use of antiangiogenesis agents with cytotoxic chemotherapy in mouse lung and lung and breast cancer models. In: E. M. Greenspan (ed.), Chemotherapy Foundation Symposium XV. Innovative Cancer Therapy for Tomorrow, pp. 16-17. New York: The Chemotherapy Foundation, 1997.
25. Castronova, V., and Belotti, D. TNP-470 (AGM-1470): mechanism of action and early clinical development. Eur. J. Cancer, 3A: 2520-2527, 1996.
26. Teicher, B. A., Emi, Y., Kakeji, Y., and Northey, D. TNP-470/mimocycline/cytotoxic therapy: a systemic approach to cancer therapy. Eur. J. Cancer, 3A:2461-2473, 1996.
27. Folkman, J. Angiogenesis inhibitors: from laboratory to clinic. In: E. M. Greenspan (ed.), Chemotherapy Foundation Symposium XV. Innovative Cancer Therapy for Tomorrow, pp. 14-15. New York: The Chemotherapy Foundation, 1997.
28. Pluda, J. M., and Parkinson, D. R. Clinical implication of tumor-associated neovascularization and current antiangiogenesis strategies for the treatment of malignancies of pancreas. Cancer (Phila.), 78: 680-687, 1996.
29. Rasmussen, H. Matrix metalloproteinase inhibition as a potential anticancer strategy: an overview of preclinical and clinical data with batimastat and marimastat. In: E. M. Greenspan (ed.), Chemotherapy Foundation Symposium XV. Innovative Cancer Therapy for Tomorrow, pp. 15-16. New York: The Chemotherapy Foundation, 1997.
30. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin. An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.